The Betami-Danblock Trial
The BETAMI-DANBLOCK trial evaluates the safety of discontinuing beta-blockers after myocardial infarction (MI) in patients with preserved or mildly reduced left ventricular ejection fraction (LVEF) (>40%) in the modern percutaneous coronary intervention (PCI) and secondary prevention era.
The trial randomized 5,574 patients within 14 days of MI to either beta-blocker therapy or no beta-blocker, with a median follow-up of 3.5 years.
Results
The primary endpoint, all-cause mortality or major adverse cardiac events (MACE), including recurrent MI, unplanned revascularization, heart failure (HF), ischemic stroke, and malignant ventricular arrhythmia, was significantly reduced with beta-blockers (hazard ratio 0.85, p=0.03).
The primary endpoint is significantly reduced with beta-blockers.
Author's summary: Beta-blockers reduce mortality and MACE after MI.
More News
- Liquid assets: November 2025
- GRID Powers Up: XSite Braehead Unveils Bold New Identity
- NHS launches AI trial to diagnose prostate cancer up to a month faster
- Gmail Data Breach: 183 million accounts exposed in massive leak
- £160bn in surplus assets: Discover how Mercer is helping unlock it
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025
- ‘Like It Was Yesterday’: The 1985 Villanova Football Team Reunited For Its 40th Anniversary
- The mentoring methods you need to try
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks